Document is current
Any future updates will be listed below
-
Authors
Díaz, Luis Antonio https://orcid.org/0000-0002-8540-4930
Pose, Elisa
Israelsen, Mads https://orcid.org/0000-0001-9443-5846
Loomba, Rohit https://orcid.org/0000-0002-4845-9991
- License Information
-
More Information
Article History
Accepted: 15 July 2026
First Online: 18 August 2026
Ethics
Competing interests: E.P. declares consultancy fees for GlaxoSmithKline. R.L. serves as a consultant to Aardvark Therapeutics, Altimmune, Anylam/Regeneron, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Bristol Myers Squibb, CohBar, Eli Lilly, Galmed, Gilead, Glympse bio, Hightide, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc., Madrigal, Metacrine, Inc., NGM Biopharmaceuticals, Novartis, Novo Nordisk, Merck, Pfizer, Sagimet, Theratechnologies, 89 bio, Terns Pharmaceuticals and Viking Therapeutics. In addition, his institutions received research grants from Arrowhead Pharmaceuticals, AstraZeneca, Boehringer-Ingelheim, Bristol Myers Squibb, Eli Lilly, Galectin Therapeutics, Galmed Pharmaceuticals, Gilead, Hanmi, Intercept, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Novo Nordisk, Merck, Pfizer, Sonic Incytes and Terns Pharmaceuticals. He is a co-founder of LipoNexus Inc. The other authors declare no competing interests.
